LBA39 Updated efficacy and safety data from IMbrave050: Phase III study of adjuvant atezolizumab (atezo) + bevacizumab (bev) vs active surveillance in patients (pts) with resected or ablated high-risk hepatocellular carcinoma (HCC)

Adam C. Yopp, M. Kudo, Mingkai Chen, Ann‐Lii Cheng, Ahmed O. Kaseb, H.C. Lee, Songbing Qin, Edward Cha, Stephen P. Hack, Qinshu Lian, J. Spahn, Chih‐Chien Wu, Pierce K. H. Chow